Journal · Updated 2026-08-11
Trimi Review 2026: The $99/$125 Annual Plans, and the $1,500 Question
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Trimi publishes the lowest per-month-equivalent compounded prices we track — ninety-nine dollars a month for semaglutide and one hundred twenty-five for tirzepatide, on annual plans billed as a single upfront payment of roughly eleven hundred eighty-eight and fifteen hundred dollars respectively — with a plain 503A disclosure and, per its own materials, no published month-to-month rate at all. On our computed rankings that makes Trimi (tied with LumiMeds) the twelve-month tirzepatide leader and a co-holder of the ninety-nine-dollar semaglutide floor. The defining fact isn't the rate; it's the shape: the full year's cost is committed on day one, in a market whose 2026 story is consolidation, pivots, and exits — which converts Trimi's refund-and-cancellation clause from fine print into the actual price of the deal.
The structure: lowest rate, highest concentration
Annual upfront billing is a legitimate business structure — it's how Trimi funds the lowest figures in the market — and it concentrates every risk this market carries into a single transaction. Enroll in month one and the program's month-nine solvency, compliance posture, and pharmacy relationships are all things you've already paid for; our 2026 ledger is the base-rate document for why that matters. The comparison that frames the decision: bmiMD reaches one thirty-nine tirzepatide and ninety-nine semaglutide on twelve-month tiers billed monthly — fourteen dollars a month more on tirzepatide, identical on semaglutide — for month-at-a-time exposure instead of a lump sum. Trimi's tirzepatide edge over that safer shape is one hundred sixty-eight dollars a year; its semaglutide edge is zero. That arithmetic, stated once, is most of the review.
The questions that are the price
Before wiring the year: the refund clause, verbatim — what returns if you cancel in month two, month six, month ten; whether unused months refund pro-rata, at the annual rate or re-billed at a higher monthly one; and what happens to the balance if the program itself winds down or loses your state. The pharmacy: the plain 503A disclosure is a start — get the name, run the fifteen minutes. The payment rail: a credit card's dispute window is the only practical backstop on a prepaid year, which makes paying any other way an unforced error. Our records carry Trimi at "reported" from July 2026 first-party figures with our capture pending; nothing adverse is on file, and nothing is confirmed — the standing condition of this market's newer low-cost tier, and the reason the questions above are load-bearing.
Who the deal fits
The honest profile: a semaglutide buyer gains nothing here over bmiMD's monthly-billed ninety-nine — same rate, safer shape — so Trimi's real market is the tirzepatide annual buyer chasing the absolute floor, who has read the refund clause, pays by credit card, has verified the pharmacy, and prices the one-sixty-eight annual saving against a year of counterparty exposure with open eyes. For everyone else — anyone uncertain they'll stay the year, anyone who couldn't absorb losing the balance, anyone unwilling to do the clause-reading — the no-commitment tier at one sixty-nine to one seventy-nine exists precisely to be chosen instead, and choosing it is not overpaying; it's buying the exit.
Questions people ask
How much does Trimi cost?
$99 a month for compounded semaglutide and $125 for tirzepatide as annual-plan equivalents — billed as single upfront payments of about $1,188 and $1,500 respectively. No month-to-month rate is published. On our computed rankings that's the twelve-month tirzepatide floor (tied with LumiMeds) and a share of the $99 semaglutide floor.
Is Trimi's $125 tirzepatide worth the upfront payment?
The arithmetic: it beats bmiMD's monthly-billed $139 twelve-month tier by $168 a year, in exchange for committing ~$1,500 on day one in a consolidating market. It's defensible for a committed annual buyer who reads the refund clause verbatim, pays by credit card, and verifies the pharmacy — and a poor fit for anyone uncertain about the full year. On semaglutide the upfront structure buys nothing: bmiMD matches $99 billed monthly.
What happens to my money if Trimi shuts down mid-year?
That is exactly the question to get answered in writing before enrolling — the refund clause is effectively the price of the deal. Practical protections: the clause verbatim (pro-rata terms, wind-down terms), payment by credit card for the dispute window, and screenshots of the enrollment terms. Our records carry no adverse flags and no confirmations either; the status is 'reported, capture pending.'
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.